Drugs / FTX-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06617546 | Oct 2024 → Apr 2025 | — | Find Therapeutics | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-06-02 | Find Therapeutics | Results First Peer-Reviewed Publication on FTX-101 is Now Online findtherapeutics.com ↗
Through a series of in vitro experiments, the study shows how FTX-101 disrupts semaphorin 3A (Sema3A) signaling, a key inhibitor of oligodendrocyte precursor cell (OPC) recruitment and differentiation. |
| 2024-08-27 | Find Therapeutics | Regulatory FDA clears Find’s IND for Phase 1 study of FTX-101 findtherapeutics.com ↗
We are pleased to announce that the U.S. Food and Drug Administration (“FDA”) has cleared its Investigational New Drug (“IND”) application for FTX-101, enabling the company to initiate its planned Phase 1 clinical study of FTX-101 in healthy volunteers. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-06-02 | Find Therapeutics | First Peer-Reviewed Publication on FTX-101 is Now Online findtherapeutics.com ↗ |
| 2025-04-10 | Find Therapeutics | Two key experts joining us to accelerate the development of FTX-101 findtherapeutics.com ↗ |
| 2024-10-20 | Find Therapeutics | FTX-101 Phase 1 Clinical Trial Launched findtherapeutics.com ↗ |
| 2024-08-27 | Find Therapeutics | FDA clears Find’s IND for Phase 1 study of FTX-101 findtherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FTX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06617546 ↗ |
| Modality | Peptide | “FTX-101 is a first-in-class, synthetic peptide” NCT06617546 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT06617546 ↗ |